Word: squibbs
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
Pharmaceutical giant Bristol-Myers Squibb has been using videoconferencing since 1991, when it paid $500,000 to build a special room with enough enhancements to ensure optimal quality. In recent years Bristol-Myers has used the technology to connect as many as 130 sites for one meeting, allowing scattered researchers to compare clinical data and discuss projects. "We use it in all aspects of our operations, from discovery to development to commercialization," says Mark Lamon, who oversees videoconferencing for the company's research-and-development unit...
...swore they would steer clear of risky drug development and stick to peddling genetic information. But many are now busy recasting themselves as little pharmaceutical firms and buying up smaller companies to fill the holes in their drug-development technology. Meanwhile, big drugmakers such as Aventis and Bristol-Myers Squibb, under pressure to jump-start their slowing rates of drug discovery, are investing billions of dollars in collaborations with biotech firms to mine the genome for new medicines...
Bristol-Myers Squibb has stepped forward in recent weeks to do its part in the fight against bioterrorism. It was one of several companies that offered the government free supplies of drugs believed to be effective against anthrax. It also offered the feds a fully-funded team of scientists with expertise in bacterial research to help fight...
...message may be getting through. Last month Merck and Bristol-Myers Squibb slashed the price offered to African countries for anti-AIDS "cocktails" to a fraction of what's charged in industrialized countries. One Bristol-Myers AIDS drug, Zerit, now costs just $54 a year in Africa; in the U.S., patients pay $3,589. This month, six other firms assured U.N. Secretary-General Kofi Annan they too would continue lowering prices. But at a conference in Norway last week with officials from the World Health Organization and World Trade Organization, some industry leaders resisted calls for further discounts. Said Bill...
Galbraith says the opportunities are pretty widespread, but Bristol Myers Squibb and American Home Products are his favorites. Drug analyst Barbara Ryan of Deutsche Banc Alex. Brown concurs: she says estimates for Bristol's earnings are too low--she's penciling in 13% or 14% annually over the next three years. And now that the fen-phen fiasco is behind American Home, she says, the company can concentrate on drugs like Enbrel for rheumatoid arthritis...